Page last updated: 2024-10-31

mirtazapine and Basal Ganglia Diseases

mirtazapine has been researched along with Basal Ganglia Diseases in 3 studies

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guo, MY1
Etminan, M1
Procyshyn, RM1
Kim, DD1
Samii, A1
Kezouh, A1
Carleton, BC1
Nagata, T1
Shinagawa, S1
Tagai, K1
Nakayama, K1
Robertson, VB1
Wilson, MS1

Other Studies

3 other studies available for mirtazapine and Basal Ganglia Diseases

ArticleYear
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:4

    Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxeti

2018
A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease.
    International psychogeriatrics, 2013, Volume: 25, Issue:7

    Topics: Antidepressive Agents, Tricyclic; Basal Ganglia Diseases; Depressive Disorder; Female; Hallucination

2013
Neurotensin receptor agonists and antagonists for schizophrenia.
    The American journal of psychiatry, 2005, Volume: 162, Issue:3

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Data Interpretation, Statistical; Humans; Mianserin; M

2005